Close to the Russian Direct Investment Fund (RDIF) announcing a partnership with Dr. Reddy’s Laboratories Ltd for the distribution of the Russian covid-19 – Sputnik V vaccine in India, the Soviet nation’s health minister, Mikhail Murashko, in a statement the Moscow Times said that nearly 14% of patients who received the vaccine reported side effects.
One in seven volunteers have complained of side effects including muscle weakness and pain after taking Russia’s highly touted coronavirus vaccine, Russia’s health minister quoted in Moscow Times said on Tuesday. Murashko said symptoms “stabilize” the next day. Complications are outlined in the instructions and are predictable, “he said, quoted in the newspaper.
Preliminary results of the human clinical trial were published in the Lancet Journal on September 4. The results of two early phase non-randomized vaccine trials for Sputnik V in a total of 76 people found that two formulations of a two-part vaccine had a good safety profile with no serious adverse events detected for 42 days, and induced responses of antibodies in all participants within 21 days. However, preliminary results published in The Lancet also listed the adverse effects of the vaccine. “The most common adverse events were pain at the injection site (44/76 participants – 58%), hyperthermia (high temperature – 38/76 – 50%), headache (32/76 – 42%), asthenia (weakness or lack of energy – 21/76 – 28%), and muscle and joint pain (18/76 – 24%), “said The Lancet.
Most adverse events were mild and no serious adverse events were detected within 42 days of vaccination, The Lancet said. The authors note that these adverse effects are characteristic of those seen with other vaccines, particularly those based on recombinant viral vectors, The Lancet said.
The two-part vaccine includes two adenovirus vectors: recombinant human adenovirus type 26 (rAd26-S) and recombinant human adenovirus type 5 (rAd5-S), which have been modified to express the SARS-CoV-spike protein. two.
India and Russia are in talks about the vaccine that will be available to the Indian population. Following regulatory approval in India, RDIF, Russia’s sovereign wealth fund will supply 100 million doses of the vaccine to Dr. Reddy’s, it said in a statement Wednesday. “Deliveries could potentially begin in late 2020, subject to the completion of successful trials and registration of the vaccine by regulatory authorities in India,” the RDIF said in a statement. India will also conduct clinical trials in its own population before approving administration of the vaccine. “Results from Phase I and II have shown promise, and we will conduct Phase III trials in India to meet the requirements of Indian regulators.” said GV Prasad, Co-President and Managing Director of Dr. Reddy’s Laboratories.
On August 11, the Sputnik V vaccine developed by the Gamaleya National Research Institute of
The epidemiology and microbiology was registered by the Russian Ministry of Health and became the world’s first registered vaccine against covid-19 based on the human adenoviral vector platform.
.
